What Astellas Pharma does

Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan, formed in 2005 through the merger of Yamanouchi Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., and publicly listed on the Tokyo Stock Exchange under ticker 4503. The company develops and commercializes prescription medicines across five core therapeutic areas: oncology, ophthalmology, urology, immunology, and women's health. It operates through two business pillars: Rx, its primary pharmaceutical business using a Focus Area approach that combines innovative biologies with modalities and technologies; and Rx+, a digital health solutions platform integrating medical technology across diagnostic, preventive, therapeutic, and prognostic care. Specialty R&D operations include the Astellas Institute for Regenerative Medicine (AIRM) in Westborough, iota Biosciences (Alameda), Universal Cells (Seattle), the Astellas Life Sciences Center (Cambridge MA), and Saku-Lab Cambridge, with R&D primary focuses spanning blindness and regeneration, genetic regulation, immuno-oncology, and induced proximity.

The company monetizes through direct enterprise field sales of branded pharmaceuticals, supported by international pharmacy, early access, international import, and patient support programs that broaden therapy reach across regulatory and reimbursement environments. Astellas maintains a wholly-owned subsidiary network spanning approximately 60 country-level commercial entities across Asia Pacific, Europe, North America, Latin America, and Middle East/Africa, with manufacturing plants in Ireland (Dublin, Killorglin, Tralee) and the US (Sanford, Seattle), and regional headquarters in Northbrook (US), Addlestone (UK/Europe), and Beijing (China). Distribution is supplemented by patient access initiatives, including the Sobre a Vida program in Brazil for advanced prostate cancer patients and the Healthcare E-city virtual platform for health literacy developed in partnership with Pixit. Strategic collaborations with nonprofit R&D entities (Direct Relief, GHIT Fund, MMV, Pediatric Praziquantel Consortium, DNDi) and the Astellas Global Health Foundation extend access to therapies in low- and middle-income countries, while academic consortia and NHS Foundation Trust partnerships in the UK support service optimization across oncology, urology, and hematology pathways.

Beyond commercial operations, Astellas operates the Astellas Global Health Foundation (established 2018 through merger of three regional foundations), the Astellas Foundation for Research on Metabolic Disorders (established 1969), and the Project Commune community health initiative with CNC, Ltd. Access and sustainability metrics are publicly disclosed: 31 million+ lives impacted through AGHF funding, $37 million+ in cumulative grants worldwide, ranked 15th of 20 in the 2024 Access to Medicine Index, and more than 200 patients supported via Prograf donations in Tanzania since FY2023. Naoki Okamura serves as President and CEO.

Name

Astellas Pharma

Legal name

Astellas Pharma Inc.

Website

https://astellas.ca

Company type

Public

Founded year

2005

Operating status

Operating

Short description

Astellas Pharma is a Tokyo-headquartered global pharmaceutical company that develops and commercializes innovative prescription medicines across oncology, ophthalmology, urology, immunology, and women's health, operating in 70+ countries through direct enterprise field sales, digital health platforms, and patient access programs.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Ophthalmology treatments
• Urology treatments
• Women's health medicines

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices64 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from discovery, development, and commercialization of innovative pharmaceutical products across therapeutic areas including oncology, ophthalmology, urology, immunology, and women's health. Products are sold through direct sales channels and distributed globally.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Astellas Pharma researches, develops, manufactures, and commercializes innovative prescription medicines across five therapeutic Focus Areas: oncology, ophthalmology, urology, immunology, and women's health. The company also operates an Rx+ digital health solutions platform that integrates medical technology with pharmaceutical products across the patient journey, and runs Access to Medicines programs (early access, international pharmacy, and patient support) to broaden availability of its therapies in 70+ countries.

Product overview

Astellas Pharma is a global life sciences company with two core business pillars: (1) Rx - its primary pharmaceutical business developing and delivering innovative prescription medicines across oncology, ophthalmology, urology, immunology, and women's health through its Focus Area approach; and (2) Rx+ - its digital health solutions platform integrating innovative medical technology with cutting-edge technology throughout the patient journey. The company also operates Access to Medicines programs providing patient support, early access, and international pharmacy services. Beyond commercial medicines, Astellas maintains philanthropic initiatives through the Astellas Global Health Foundation, the Astellas Foundation for Research on Metabolic Disorders, and community health programs like Project Commune and Starlight Partner Activities. Digital health offerings include the Astellas Healthcare E-city virtual platform for health literacy education.

Differentiator

Problem solved

Functional benefit

Products and services

• Core Rx Pharmaceutical Business

Quantifiable outcome

• More than 31 million lives impacted through AGHF funding globally
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

20 partnerships are on record, tiered core and minor.

• Swiss Transplantation Society (STS)coreGTM or Marketing Partner · 1 January 2016Financial support for STS Excellence and Innovation Awards since 2016. Excellence Award endowed with CHF 20,000; Innovation Award endowed with CHF 10,000. Both awards presented every other year at STS annual meeting to advance transplant research in Switzerland.
• Pediatric Praziquantel ConsortiumcoreStrategic or Co-development Partner · 1 January 2012International public-private partnership aiming to reduce global disease burden of schistosomiasis and improve child health. Astellas participated as founding member since 2012, contributing innovative formulation technology. In December 2023, EMA granted positive CHMP scientific opinion for new pediatric treatment.
• Direct ReliefcoreStrategic or Co-development PartnerPartnership with Direct Relief ensures donated Prograf (immunosuppressive therapy) is effectively used for post-transplant patients in Tanzania. Astellas has supported more than 200 patients since FY2023. This collaboration aligns with Astellas' Access to Medicines Strategy to improve access to medicines throughout the product lifecycle.
• Medicines for Malaria Venture (MMV)coreStrategic or Co-development PartnerCollaborative research for exploration of antimalarial drug from October 2017. Initial profiling of hit compounds discovered in Screening Collaboration appear to have novel drug-like chemotypes and mechanism of action. New collaborative research agreement entered February 2022 to identify lead compounds.
• Global Health Innovative Technology Fund (GHIT Fund)coreStrategic or Co-development PartnerInternational public-private partnership fund between Japanese Government, Bill & Melinda Gates Foundation, Wellcome, and UNDP. GHIT Fund has invested approximately 29.1 billion yen in 118 projects over ten years. Astellas has contributed since inception as a partner in the third phase.
• Drugs for Neglected Diseases initiative (DNDi)coreStrategic or Co-development PartnerNot-for-profit organization engaged in development of new treatments for neglected diseases. Astellas participates in NTDs Drug Discovery Booster consortium (March 2018) for leishmaniasis and Chagas disease, alongside Eisai, Shionogi, Takeda, AstraZeneca, Celgene, Merck KGaA, and AbbVie.
• CNC, Ltd.coreStrategic or Co-development PartnerProject Commune collaboration implementing community health initiatives with Community Nurses in Japan. Activities include Good Meddlers Award Competition, health consultation events, dementia awareness events, and practical courses for hospital staff. Expanded to isolated communities in United States with multilingual Community Health Workers supporting pregnant women.
• PixitcoreTechnology or IntegrationLocal Brazilian tech company partnered with Astellas to develop the virtual 'Astellas Healthcare E-city' platform. Launched in 2023 with educational content on early diagnosis and prevention of gastric cancer. Expanded in 2024 with women's health content and in 2025 to Colombia.
• Torbay & South Devon NHS Foundation TrustminorStrategic or Co-development PartnerCollaborative working project for prostate cancer service optimization following ABPI Code of Practice guidelines.
• Nottingham University Hospitals NHS Foundation TrustminorStrategic or Co-development PartnerCollaborative working project for prostate cancer service optimization following ABPI Code of Practice guidelines.
• Portsmouth Hospitals University NHS TrustminorStrategic or Co-development PartnerCollaborative working project for prostate cancer service optimization following ABPI Code of Practice guidelines.
• Sheffield Teaching Hospitals NHS Foundation TrustminorStrategic or Co-development PartnerCollaborative working project for prostate cancer service optimization following ABPI Code of Practice guidelines.
• The Christie NHS Foundation TrustminorStrategic or Co-development PartnerCollaborative working project for bladder cancer pathway optimization following ABPI Code of Practice guidelines.
• The Churchill Hospital, Oxford University Hospitals NHS Foundation TrustminorStrategic or Co-development PartnerCollaborative working project for bladder cancer pathway optimization following ABPI Code of Practice guidelines.
• The Clatterbridge Cancer Centre NHS Foundation TrustminorStrategic or Co-development PartnerCollaborative working project for bladder cancer pathway optimization following ABPI Code of Practice guidelines.
• Addenbrookes HospitalminorStrategic or Co-development PartnerCollaborative working project for AML (Acute Myeloid Leukemia) service optimization following ABPI Code of Practice guidelines.
• Mount Vernon Cancer Centre, East and North Hertfordshire NHS TrustminorStrategic or Co-development PartnerCollaborative working project for NMP (Nomacopan) patient initiated follow-up toolkit following ABPI Code of Practice guidelines.
• South Doc Services (SDS)minorStrategic or Co-development PartnerCollaborative working project for OAB (Overactive Bladder) service transformation following ABPI Code of Practice guidelines.
• Swiss Cancer InstitutecoreGTM or Marketing PartnerPartnership to confer Swiss Cancer Institute / Astellas GU-GI Research Award endowed with CHF 30,000. Focus on genitourinary and/or gastrointestinal oncology research with tangible improvements for patient management and outcomes in Switzerland.
• Astellas Foundation for Research on Metabolic DisorderscoreStrategic or Co-development PartnerEstablished in 1969, awards grants for epoch-making research and nurturing brilliant young talent. In FY2024, awarded 160 million yen for research donations to 80 researchers out of 1,155 applicants, and 55.66 million yen for overseas study subsidies to 11 researchers.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Takeda Pharmaceutical: Japan's largest pharmaceutical company and most direct domestic peer to Astellas; competes in oncology, gastroenterology, rare diseases, and neuroscience with similar global commercial scale and Japan-listed equity profile.
• Daiichi Sankyo: Japanese peer pharma with global oncology focus (antibody-drug conjugates,DXd platform) that overlaps directly with Astellas's oncology franchise; both are mid-large Japanese innovators with US/EU commercial arms.
• Eisai: Japanese peer with overlapping oncology and neurology franchises, also co-founder of the DNDi NTDs Drug Discovery Booster alongside Astellas; comparable Japan-listed innovator with global footprint.
• Otsuka Pharmaceutical: Japanese peer pharma with significant oncology, CNS, and rare-disease programs; comparable scale and therapeutic-area overlap (urology/oncology adjacencies) make it a directly comparable mid-tier Japanese innovator.
• Chugai Pharmaceutical: Roche-affiliated Japanese innovator with strong oncology and immunology franchises directly comparable to Astellas's Focus Areas; useful peer for Japan-domiciled pharma valuation comparables.
• Shionogi: Japanese peer pharma with overlapping global health / infectious disease commitments (also a DNDi partner) and oncology/immunology pipeline; smaller-cap but direct comparable as a Japan-listed innovator.
• Sumitomo Pharma: Japanese peer with oncology, women's health, and urology adjacencies; operates a global commercial footprint that directly overlaps Astellas's geographic reach in oncology and specialty care.

Broad incumbents

• Pfizer: Global pharma incumbent whose oncology and urology franchises (e.g., Xtandi co-promote history with Astellas) directly overlap with Astellas's commercial footprint; broad incumbent offering portfolio breadth Astellas lacks.
• Novartis: Global pharma incumbent with overlapping therapeutic focus in oncology and ophthalmology, both areas where Astellas operates; comparable global commercial scale and innovator R&D model.
• Bayer (Pharmaceuticals): Global incumbent whose pharmaceutical division overlaps with Astellas in oncology and women's health; comparable diversified pharma model with global distribution muscle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCQ9_3AI4aHQdJ9N5t0i3WYA
• LinkedInlinkedin.com/company/astellas-pharma-canada-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries30 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astellas Pharma